mRNA-LNP Vaccines Slash Allergic Asthma Symptoms Using COVID Vaccine Tech
Researchers repurpose mRNA-lipid nanoparticle technology to prevent and treat allergic asthma in mice, achieving ~100-fold reduction in airway eosinophils.
Summary
Scientists at Cincinnati Children's Hospital and the University of Pennsylvania have adapted the same mRNA-lipid nanoparticle (LNP) platform used in COVID-19 vaccines to target allergic diseases. In mouse models of asthma triggered by ovalbumin and house dust mite allergens, two doses of allergen-encoding mRNA-LNPs reduced airway eosinophils by nearly 100-fold, suppressed Th2 immune cells driving allergic inflammation, lowered IgE antibodies, and protected against airway hyperresponsiveness. The vaccine shifted immune responses from allergy-promoting Th2 pathways toward protective Th1 and cytotoxic CD8+ T cell activity. Critically, the therapy worked in both preventive and established disease models, suggesting potential for treatment as well as prevention of allergic conditions.
Detailed Summary
Allergic diseases affect roughly 30% of the global population, yet current therapies — including allergen immunotherapy, anti-cytokine biologics, and corticosteroids — remain limited in efficacy, durability, and practical convenience. This study from Rochman et al., published in the Journal of Clinical Investigation, asks whether the same nucleoside-modified mRNA encapsulated in lipid nanoparticles (mRNA-LNP) technology that powered COVID-19 vaccines can be repurposed to reprogram the immune system away from allergic responses. The hypothesis is that delivering allergen-encoded mRNA intramuscularly would instruct the immune system to mount a Th1-dominant, IgG-rich response rather than the Th2-driven, IgE-heavy response that underlies allergy.
The researchers first validated their OVA-mRNA-LNP construct using adoptively transferred OVA-specific OTII T cells. Immunization with 2–5 µg OVA-mRNA-LNP produced robust OTII cell expansion (>80% expressing activation marker CD44), elevated IFN-γ and TNF-α production, and a Bcl6+PD-1+ follicular helper T cell phenotype — all hallmarks of a Th1/Tfh response. A dose-dependent increase in OVA-specific IgG1, IgG2a, and IgG2b was observed in serum 18 days post-treatment. Critically, no IL-4, IL-17A, or Foxp3 elevation was seen, ruling out Th2 or Treg skewing from the vaccine itself.
In the primary acute asthma model, mice given two doses of OVA-mRNA-LNP prior to OVA+Alum sensitization and airway challenge showed eosinophil levels in bronchoalveolar lavage fluid (BALF) nearly 100-fold lower than LNP-treated controls, confirmed by both flow cytometry and anti-MBP histologic staining. Th2-associated cytokines IL-4 and IL-5 in BALF were significantly decreased, while Th1-associated chemokines MIP-1α/β, IP-10, and IFN-γ were elevated. Allergen-specific IgE was substantially reduced whereas IgG1 and IgG2 were strongly induced. Mice were also protected from methacholine-induced airway hyperresponsiveness and showed markedly reduced goblet cell mucus production on PAS staining. These protective effects were replicated in a chronic asthma model with prolonged OVA exposure.
Extending beyond the OVA model, the team tested HDM allergen extract and the major HDM component Der p1 — both clinically relevant human allergens. HDM-mRNA-LNP and Der-p1-mRNA-LNP vaccines similarly attenuated eosinophilia, Th2 responses, and airway hyperresponsiveness in sensitized mice. Strikingly, treatment with Der-p1-mRNA-LNP after established sensitization (therapeutic model) also reduced allergic airway inflammation, demonstrating that the approach can treat existing allergy rather than only prevent it. A CD8+CD38+KLRG– T cell population, previously identified as a signature of SARS-CoV-2 mRNA vaccination in humans, was elicited by allergen mRNA-LNP vaccines in mice, suggesting a conserved cross-species immune mechanism.
A particularly noteworthy experiment combined mRNA-LNP vaccination with the mTOR inhibitor rapamycin. Rapamycin significantly reduced the CD8+ T cell response to vaccination, yet the anti-allergic protective effect — suppression of eosinophilia, Th2 cells, and airway hyperresponsiveness — was preserved in the preventive model. This finding suggests that CD8+ T cells are not required for allergen-specific mRNA-LNP protection against allergy and implies these vaccines could potentially be used in immunocompromised patients or those taking mTOR inhibitors. Caveats include the exclusively murine scope of the work, uncertainty about optimal dosing intervals for human translation, and the need for clinical trials to confirm safety and efficacy in allergic patients.
Key Findings
- Two doses of OVA-mRNA-LNP (2–5 µg i.m.) reduced airway eosinophils by approximately 100-fold compared with LNP controls in the preventive asthma model
- Allergen-specific mRNA-LNP strongly induced protective IgG1, IgG2a, and IgG2b antibodies while markedly reducing allergen-specific IgE upon sensitization
- BALF Th2 cytokines IL-4 and IL-5 were significantly decreased, while Th1 chemokines IFN-γ, IP-10, MIG, and RANTES were elevated in OVA-mRNA-LNP–treated mice
- Mice immunized with OVA-mRNA-LNP were protected from methacholine-induced airway hyperresponsiveness and showed reduced lung mucus production (PAS staining) in both acute and chronic asthma models
- HDM-mRNA-LNP and Der-p1-mRNA-LNP vaccines replicated anti-allergic effects against clinically relevant house dust mite allergens, including in a therapeutic (post-sensitization) model
- A CD8+CD38+KLRG– T cell signature, identical to that seen after SARS-CoV-2 mRNA vaccination in humans, was elicited by allergen mRNA-LNP in mice, indicating a conserved cross-species mechanism
- Co-administration of rapamycin (mTOR inhibitor) abolished the vaccine-induced CD8+ T cell response but preserved anti-allergic protection in the preventive model
Methodology
This was a preclinical mouse study using C57BL/6 and BALB/c mice with acute, chronic, and therapeutic models of allergic asthma induced by OVA+Alum sensitization, HDM extract, and recombinant Der p1 allergen, with intramuscular injection of N1-methylpseudouridine-modified mRNA-LNPs (doses 0–5 µg). Outcomes included BALF differential cell counts by flow cytometry, lung histology (H&E, anti-MBP, PAS staining), serum allergen-specific antibodies (IgE, IgG1, IgG2a/b), airway hyperresponsiveness by methacholine challenge, BALF cytokine multiplex, and qPCR of lung tissue. Control groups included PBS, empty LNP, and allergen protein + Alum groups; no formal power calculations or p-values were reported in the extracted text, but group comparisons were performed across multiple independent experiments.
Study Limitations
This study is entirely preclinical, conducted in inbred mouse models that imperfectly recapitulate the heterogeneous human allergic disease spectrum; optimal mRNA dose, schedule, and delivery parameters for human use remain undetermined. The paper does not report formal statistical tests or p-values in the available text, making precise effect size quantification difficult. The authors acknowledge funding from the Food Allergy Fund (a private source), and some co-authors (Weissman, Alameh) are affiliated with mRNA-LNP technology development at UPenn, representing potential conflicts of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.